A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Tumours
- Focus Therapeutic Use
- Acronyms AGNOSTOS
- 11 Oct 2016 Planned number of patients changed from 120 to 132.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 20 Nov 2015 New trial record